Nitro-aspirin inhibits MCF-7 breast cancer cell growth: Effects on COX-2 expression and Wnt/β-catenin/TCF-4 signaling

Biochemical Pharmacology

Volumn 78, Issue 10, 2009, Pages 1298-1304

  Nath, Niharika ^a,b   Vassell, Rashida ^a   Chattopadhyay, Mitali ^a   Kogan, Marsel ^b   Kashfi, Khosrow ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Catenin; Aspirin; Breast cancer; Cancer; Chemoprevention; COX 2; NO releasing aspirin; Protein kinase C

Indexed keywords

2 (ACETYLOXY)BENZOIC ACID 3 (NITROOXY METHYL)PHENYL ESTER; 2 (ACETYLOXY)BENZOIC ACID 4 (NITROOXY METHYL)PHENYL ESTER; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; PROTEIN KINASE C INHIBITOR; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL STRAIN MCF 7; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; ISOMER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTICARCINOGENIC AGENTS; ASPIRIN; BETA CATENIN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; DOWN-REGULATION; ENZYME INDUCTION; FEMALE; GENES, REPORTER; HUMANS; INHIBITORY CONCENTRATION 50; ISOMERISM; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; WNT PROTEINS;

EID: 70349454049     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.104     Document Type: Article

References (43)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Reeder J.G., and Vogel V.G. Breast cancer risk management. Clin Breast Cancer 7 (2007) 833-840
3. Vogel V.G. Chemoprevention strategies 2006. Curr Treat Options Oncol 8 (2007) 74-88
4. Brown P.H., and Lippman S.M. Chemoprevention of breast cancer. Breast Cancer Res Treat 62 (2000) 1-17
5. Schiff R., Massarweh S., Shou J., and Osborne C.K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9 (2003) 447S-454S
6. Michaelson J.S., and Leder P. Beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 20 (2001) 5093-5099
7. Hatsell S., Rowlands T., Hiremath M., and Cowin P. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 8 (2003) 145-158
8. Moon R.T., Kohn A.D., De Ferrari G.V., and Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5 (2004) 691-701
9. van de Wetering M., Barker N., Harkes I.C., van der Heyden M., Dijk N.J., Hollestelle A., et al. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res 61 (2001) 278-284
10. Turashvili G., Bouchal J., Burkadze G., and Kolar Z. Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73 (2006) 213-223
11. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
12. Agrawal A., and Fentiman I.S. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62 (2008) 444-449
13. Johnson T.W., Anderson K.E., Lazovich D., and Folsom A.R. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 11 (2002) 1586-1591
14. Marshall S.F., Bernstein L., Anton-Culver H., Deapen D., Horn-Ross P.L., Mohrenweiser H., et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97 (2005) 805-812
15. Jacobs E.J., Thun M.J., Bain E.B., Rodriguez C., Henley S.J., and Calle E.E. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99 (2007) 608-615
16. Takkouche B., Regueira-Mendez C., and Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100 (2008) 1439-1447
17. Bjorkman D.J. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 107 (1999) 3S-8S discussion S-10S
18. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711
19. Kashfi K., Ryan Y., Qiao L.L., Williams J.L., Chen J., Del Soldato P., et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 303 (2002) 1273-1282
20. Burgaud J.L., Ongini E., and Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann NY Acad Sci 962 (2002) 360-371
21. Rigas B., and Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 10 (2004) 324-330
22. Williams J.L., Kashfi K., Ouyang N., del Soldato P., Kopelovich L., and Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun 313 (2004) 784-788
23. Ouyang N., Williams J.L., Tsioulias G.J., Gao J., Iatropoulos M.J., Kopelovich L., et al. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res 66 (2006) 4503-4511
24. Rao C.V., Reddy B.S., Steele V.E., Wang C.X., Liu X., Ouyang N., et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 5 (2006) 1530-1538
25. Nath N., Kashfi K., Chen J., and Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc Natl Acad Sci USA 100 (2003) 12584-12589
26. Nath N., Labaze G., Rigas B., and Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Biochem Biophys Res Commun 326 (2005) 93-99
27. Williams J.L., Nath N., Chen J., Hundley T.R., Gao J., Kopelovich L., et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 63 (2003) 7613-7618
28. Dannenberg A.J., and Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 (2003) 431-436
29. Kashfi K., and Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70 (2005) 969-986
30. Peng B.W., Lin J.Y., and Zhang T. Toxoplasma gondii induces prostaglandin E2 synthesis in macrophages via signal pathways for calcium-dependent arachidonic acid production and PKC-dependent induction of cyclooxygenase-2. Parasitol Res 102 (2008) 1043-1050
31. Zhang L., Jiang L., Sun Q., Peng T., Lou K., Liu N., et al. Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. Mol Cell Biochem 305 (2007) 19-26
32. Jerde T.J., Mellon W.S., Bjorling D.E., Checura C.M., Owusu-Ofori K., Parrish J.J., et al. Stretch induction of cyclooxygenase-2 expression in human urothelial cells is calcium- and protein kinase C zeta-dependent. Mol Pharmacol 73 (2008) 18-26
33. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40 (1997) 1347-1365
34. Liu J.F., Crepin M., Liu J.M., Barritault D., and Ledoux D. FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun 293 (2002) 1174-1182
35. Pedraza-Alva G., Sawasdikosol S., Liu Y.C., Merida L.B., Cruz-Munoz M.E., Oceguera-Yanez F., et al. Regulation of Cbl molecular interactions by the co-receptor molecule CD43 in human T cells. J Biol Chem 276 (2001) 729-737
36. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97 (2000) 4262-4266
37. Alessi D.R. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase. FEBS Lett 402 (1997) 121-123
38. Gao J., Liu X., and Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci USA 102 (2005) 17207-17212
39. Janicke R.U., Ng P., Sprengart M.L., and Porter A.G. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273 (1998) 15540-15545
40. Yeh R.K., Chen J., Williams J.L., Baluch M., Hundley T.R., Rosenbaum R.E., et al. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?. Biochem Pharmacol 67 (2004) 2197-2205
41. Han A., Song Z., Tong C., Hu D., Bi X., Augenlicht L.H., et al. Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol 583 (2008) 26-31
42. Rigas B., and Shiff S.J. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenases, and the cell cycle. Their interactions in colon cancer. Adv Exp Med Biol 470 (1999) 119-126
43. Gansauge S., Nussler A.K., Beger H.G., and Gansauge F. Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. Cell Growth Differ 9 (1998) 611-617